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Abstract Background
Fms-like tyrosine gene mutations are frequent in acute promyelocytic leukemia but their prognostic value is not well established.
Design and methods
We evaluated FLT3 internal tandem duplication and D835 mutations in patients treated with all-trans retinoic acid and anthracycline-based chemotherapy enrolled in two subsequent trials of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) and Hemato-Oncologie voor Volwassenen Nederland (HOVON) groups between 1996 and 2005.
Results

FLT3
internal tandem duplication and D835 mutation status were available in 306 (41%) and 213 (29%) patients, respectively. Sixty-eight (22%) and 20 (9%) patients had internal tandem duplication and D835 mutations, respectively. Internal tandem duplication was correlated with a higher white blood cell and blast counts, lactate dehydrogenase, relapse-risk score, fever, hemorrhage, coagulopathy, BCR3 isoform, M3 variant subtype, and expression of CD2, CD34, human leukocyte antigen (HLA)-DR, and CD11b surface antigens. D835 was not significantly associated with any clinical or biological characteristic. Univariate analysis showed a higher relapse and a lower survival in FLT3 internal tandem duplication positive patients, while no impact was observed in relation to D835. However the prognostic value of FLT3 internal tandem duplication was not retained in the multivariate analysis.
Conclusions DOI: 10.3324/haematol.2011.044933 
Introduction
Constitutive activation of the FLT3 (fms-like tyrosine kinase 3) receptor due to internal tandem duplication (FLT3-ITD) and a point mutation in the activation loop (FLT3-D835) may confer a proliferative and survival advantage to acute myeloid leukemia (AML) blasts. 1, 2 The presence of FLT3 mutations, in particular of the ITDs, has been consistently associated with a worse outcome in patients with AML with normal cytogenetics or intermediate risk cytogenetics. 3, 4 However, the prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia (APL), a form of AML characterized by the specific t (15;17) , is still a matter of controversy. Although several studies in APL have reported an association between FLT3-ITDs and several characteristics, including elevated white blood cell (WBC) count, BCR3 isoform, and microgranular morphology (M3v), [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] the prognostic value of these mutations remains to be established. Two previous studies have dealt with a multivariate analysis including both WBC, a well-known poor risk factor in APL, 16 and ITDs in order to assess the independent value of each one. The study by Gale et al. 12 showed that the WBC count was the sole independent prognostic factor for relapse and survival. In contrast, Chillón et al. 17 analyzed the prognostic value of ITDs ratio and size and found that both ITDs length and WBC count were independent prognostic factors in APL. Regarding the FLT3-D835 mutation, most authors were unable to demonstrate an impact on prognosis, 7, [9] [10] [11] while some studies have reported worse outcomes when D835 mutation is present. 
Design and Methods
Patients and eligibility
Between Qualitative FLT3-ITD and D835 mutations were studied in DNA or cDNA samples following the methods described by Nakao et al. 23 and Moreno et al. 24 In selected cases, the presence of FLT3-ITD and D835 mutations were confirmed by sequencing of the amplified products.
Quantitative assessment of FLT3-ITD mutations was performed only in patients with available genomic DNA, by Genescan analysis using a fluorescently labeled primer with 6-FAM to determine allelic FLT3-ITD ratio and size, following the method described by Thiede et al. 25 If several mutant alleles were detected by Genescan, the mutant allele with the higher allelic ratio was selected for the size analyses. with very low number of copies (<5 copies) by RQ-PCR were confirmed with a low sensitivity method (nested RT-PCR assay). Molecular relapse was defined as the reappearance of PCR positivity in two consecutive BM samples at any time after consolidation therapy. 28 Genetic diagnosis of APL using PCR, anti-PML staining or cytogenetic tests was required for the diagnosis of overt hematologic relapse.
Definitions and Study Endpoints
Diagnosis and gradation of the differentiation syndrome (DS) was made according to the previously defined criteria. 29 Coagulopathy was defined as a prolonged prothrombin time and/or activated partial thromboplastin time in addition to hypofibrinogenemia and/or increased levels of fibrin degradation products or D-dimers. Patients were classified as having t(15;17) with or without additional chromosomal abnormalities accordingly to previously defined criteria. 30 The patient performance status at diagnosis was measured using the Eastern Cooperative Oncology Group (ECOG) scale. 
Patient characteristics according to FLT3 mutation status
The main clinical and biological characteristics of the patients according to FLT3 mutation status are summarized in Tables 1 and 2 . FLT3-ITD was significantly associated with higher WBC, higher relapse-risk score, blasts in PB >70%, BCR3 (Table 2) .
Induction Outcome
The overall induction death rate of the series was 8.8%. As it is shown in Table 3 /L (P<0.001), age >60 years (P=0.001), and creatinine levels >1.4 mg/dL (P=0.02) as independent prognostic factors for induction death.
No significant associations were found with the induction outcomes according to the FLT3-D835 mutation status (Table 4) .
Post-remission outcomes
Relapse-free survival. Univariate analysis showed a shorter 5-year RFS in FLT3-ITD positive compared to FLT3-ITD negative patients (77% vs. 88% P=0.02) and no impact of FLT3-D835 mutation status (93% vs. 84% P=0.29) (Figure 1 and Tables 3 and 4) . We did not find showed a higher induction death and lower RFS rates among FLT3-ITD positive patients, multivariate analyses revealed that the FLT3-ITD had no independent prognostic value in patients with APL treated with ATRA and anthracycline-based chemotherapy.
As far as we know, our study represents the largest single series addressing the clinical significance of FLT3 mutations in APL. Since not all centers performed the FLT3 analyses, which were not compulsory in the initial diagnostic set, we cannot DOI: 10.3324/haematol.2011.044933 definitely exclude a selection bias. It should be noted that, although patients were from 53 institutions, the FLT3 analyses were performed in a limited number of reference laboratories. Activating mutations of FLT3 have been reported in APL in frequencies within a range of 12% to 39% for FLT3-ITD (median 21%), [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 17, 33, 34 and 6% to 22% for FLT3-D835 (median 9%). [6] [7] [8] [9] [10] [11] [12] 14, 15, 17 The incidence of these mutations in our study, 22%
and 9%, respectively, are similar. As in previous studies, 9, 11, 12, 14 in our series the simultaneous presence of both ITD and D835 mutations is extremely rare.
The mutant allelic ratio of FLT3-ITD in APL has been analyzed in two studies that reported in 30 and 19 patients median ratios of 1.0 (range 0.11 to 6.55), 11 and .66 (range 0.3 to 1.0), 17 respectively. In our series of 39 patients with available mutant allelic ratio, we found a median of .66 (range .06 to 1.3) which compared similarly with the data from Chillón et al. 17 In contrast to the study by Xue et al., 11 patients with ratio greater than 2 indicating loss of wild type allele were not observed.
In line with previous studies, 5-7.9,11-15 we found a strong association between ITDs and high WBC counts. We also found a clear correlation between ITDs and M3v and BCR3, as has previously been reported by others. [6] [7] [8] [9] [10] 12, 15 However, the relationship found between ITDs and CD34, CD2, and HLA-DR expression has not been previously noted. This relationship could be explained by the association of the ITDs with the M3v and BCR3 APLs which in turn have been shown to express more frequently the CD34, CD2, and HLA-DR surface markers. 35, 36 We confirm that high WBC counts, such as elevated LDH levels and coagulopathy, are more frequent in FLT3-ITD positive APL.
5
The increased frequencies of hemorrhage and high PB and BM blasts percentages that we report here have not previously been demonstrated. In contrast with the studies by Xue et al., 11 and Gale et al., 12 we were unable to show an association between FLT3-D835 and elevated WBC counts or any other clinical or biological characteristic.
As previously reported, 11, 13, 14, 33 patients with ITDs also in our study had an increased risk of induction death. However, the multivariate analysis made clear that this was due DOI: 10.3324/haematol.2011.044933 to the association with hyperleukocytosis, a well established risk factor for induction death. 22 An inverse relationship has been suggested in one study between a molecular remission rate and ITDs in patients treated with arsenic trioxide. 15 In the present study, an association between FLT3-ITD and molecular remissions was not apparent.
The associations reported between ITDs and OS and RFS have previously been established by univariate but not by multivariate analysis. 9, 17, 37 17 However, we should be very cautious in the interpretation of the potential prognostic impact of the ratio and size of the FLT3-ITD mutations due to the low number of datasets available.
Regarding the FLT3-D835, unlike the study by Gale et al., 12 we found no prognostic significance of this mutation in our series.
In 
